Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Organelle-derived acetyl-CoA promotes prostate cancer cell survival, migration, and metastasis via activation of calmodulin kinase II.

Yu G, Cheng CJ, Lin SC, Lee YC, Frigo DE, Yu-Lee LY, Gallick GE, Titus MA, Nutt LK, Lin SH.

Cancer Res. 2018 Mar 13. pii: canres.2392.2017. doi: 10.1158/0008-5472.CAN-17-2392. [Epub ahead of print]

PMID:
29535221
2.

Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFβRIII-p38MAPK-pS249/T252RB pathway.

Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T, Yu KJ, Liu B, Creighton CJ, Rodriguez-Canales J, Villalobos PA, Wistuba II, de Nadal E, Posas F, Gallick GE, Lin SH.

Cancer Res. 2018 Mar 7. pii: canres.1051.2017. doi: 10.1158/0008-5472.CAN-17-1051. [Epub ahead of print]

PMID:
29514796
3.

BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.

Pan T, Lin SC, Yu KJ, Yu G, Song JH, Lewis VO, Bird JE, Moon B, Lin PP, Tannir NM, Jonasch E, Wood CG, Gallick GE, Yu-Lee LY, Lin SH, Satcher RL.

Neoplasia. 2018 Jan;20(1):32-43. doi: 10.1016/j.neo.2017.11.002. Epub 2017 Nov 27.

4.

JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.

Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, Hung MC, Marks JR, Gallick GE, Lopez-Berestein G, Flores ER, Sood AK, Huang S, Yu D, Yang L, Lin C.

J Clin Invest. 2017 Dec 1;127(12):4498-4515. doi: 10.1172/JCI91553. Epub 2017 Nov 13.

5.

Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone.

Yu KJ, Li JK, Lee YC, Yu G, Lin SC, Pan T, Satcher RL, Titus MA, Yu-Lee LY, Weng WH, Gallick GE, Lin SH.

Oncotarget. 2017 Aug 24;8(43):74987-75006. doi: 10.18632/oncotarget.20489. eCollection 2017 Sep 26.

6.

Proteomics Profiling of Exosomes from Primary Mouse Osteoblasts under Proliferation versus Mineralization Conditions and Characterization of Their Uptake into Prostate Cancer Cells.

Bilen MA, Pan T, Lee YC, Lin SC, Yu G, Pan J, Hawke D, Pan BF, Vykoukal J, Gray K, Satcher RL, Gallick GE, Yu-Lee LY, Lin SH.

J Proteome Res. 2017 Aug 4;16(8):2709-2728. doi: 10.1021/acs.jproteome.6b00981. Epub 2017 Jul 18.

PMID:
28675788
7.

Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer.

Lin SC, Lee YC, Yu G, Cheng CJ, Zhou X, Chu K, Murshed M, Le NT, Baseler L, Abe JI, Fujiwara K, deCrombrugghe B, Logothetis CJ, Gallick GE, Yu-Lee LY, Maity SN, Lin SH.

Dev Cell. 2017 Jun 5;41(5):467-480.e3. doi: 10.1016/j.devcel.2017.05.005.

PMID:
28586644
8.

Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.

Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.

Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.

PMID:
28536297
9.

Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.

Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S.

Clin Cancer Res. 2017 Aug 1;23(15):4146-4154. doi: 10.1158/1078-0432.CCR-16-3138. Epub 2017 Mar 9.

PMID:
28280091
10.

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC.

Cell Rep. 2017 Feb 21;18(8):1970-1981. doi: 10.1016/j.celrep.2017.01.072.

11.

A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis.

Li C, Wang S, Xing Z, Lin A, Liang K, Song J, Hu Q, Yao J, Chen Z, Park PK, Hawke DH, Zhou J, Zhou Y, Zhang S, Liang H, Hung MC, Gallick GE, Han L, Lin C, Yang L.

Nat Cell Biol. 2017 Feb;19(2):106-119. doi: 10.1038/ncb3464. Epub 2017 Jan 23.

12.

The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study.

Dayyani F, Zurita AJ, Nogueras-González GM, Slack R, Millikan RE, Araujo JC, Gallick GE, Logothetis CJ, Corn PG.

BMC Cancer. 2016 Sep 6;16:721. doi: 10.1186/s12885-016-2723-1.

13.

Erratum: ALG-2 activates the MVB sorting function of ALIX through relieving its intramolecular interaction.

Sun S, Zhou X, Corvera J, Gallick GE, Lin SH, Kuang J.

Cell Discov. 2016 Jun 21;2:16023. doi: 10.1038/celldisc.2016.23. eCollection 2016.

14.

Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.

Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC, Hawke DH, Parikh NU, Varkaris A, Corn P, Logothetis C, Satcher RL, Yu-Lee LY, Gallick GE, Lin SH.

Cancer Res. 2015 Nov 15;75(22):4949-59. doi: 10.1158/0008-5472.CAN-15-1215. Epub 2015 Nov 3.

15.

Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.

Hahn NM, Knudsen BS, Daneshmand S, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, Corless CL, Alva AS, Shen SS, Huang F, Gertych A, Gallick GE, Mallick J, Ryan C, Galsky MD, Lerner SP, Posadas EM, Sonpavde G.

Urol Oncol. 2016 Jan;34(1):4.e11-7. doi: 10.1016/j.urolonc.2015.08.005. Epub 2015 Sep 9.

PMID:
26362343
16.

Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.

Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE.

Oncotarget. 2015 Oct 6;6(30):29161-77. doi: 10.18632/oncotarget.4971.

17.

Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.

Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE.

Clin Cancer Res. 2016 Jan 1;22(1):107-21. doi: 10.1158/1078-0432.CCR-15-0235. Epub 2015 Aug 13.

18.

The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.

Vishwamitra D, Curry CV, Alkan S, Song YH, Gallick GE, Kaseb AO, Shi P, Amin HM.

Mol Cancer. 2015 Feb 25;14:53. doi: 10.1186/s12943-015-0324-2.

19.

Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells.

Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE.

Oncotarget. 2015 Apr 30;6(12):10175-94.

20.

ALG-2 activates the MVB sorting function of ALIX through relieving its intramolecular interaction.

Sun S, Zhou X, Corvera J, Gallick GE, Lin SH, Kuang J.

Cell Discov. 2015 Jul 21;1:15018. doi: 10.1038/celldisc.2015.18. eCollection 2015. Erratum in: Cell Discov. 2016;2:16023.

21.

Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment.

Lee YC, Gajdosik MS, Josic D, Clifton JG, Logothetis C, Yu-Lee LY, Gallick GE, Maity SN, Lin SH.

Mol Cell Proteomics. 2015 Mar;14(3):471-83. doi: 10.1074/mcp.M114.039909. Epub 2014 Dec 19.

22.

Unravelling the pivotal role of Alix in MVB sorting and silencing of the activated EGFR.

Sun S, Zhou X, Zhang W, Gallick GE, Kuang J.

Biochem J. 2015 Mar 15;466(3):475-87. doi: 10.1042/BJ20141156.

23.

RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival.

Yu G, Lee YC, Cheng CJ, Wu CF, Song JH, Gallick GE, Yu-Lee LY, Kuang J, Lin SH.

Mol Cancer Res. 2015 Feb;13(2):348-57. doi: 10.1158/1541-7786.MCR-14-0384-T. Epub 2014 Sep 4.

24.

Talin1 phosphorylation activates β1 integrins: a novel mechanism to promote prostate cancer bone metastasis.

Jin JK, Tien PC, Cheng CJ, Song JH, Huang C, Lin SH, Gallick GE.

Oncogene. 2015 Apr 2;34(14):1811-21. doi: 10.1038/onc.2014.116. Epub 2014 May 5.

25.

Cadherin-11 in renal cell carcinoma bone metastasis.

Satcher RL, Pan T, Cheng CJ, Lee YC, Lin SC, Yu G, Li X, Hoang AG, Tamboli P, Jonasch E, Gallick GE, Lin SH.

PLoS One. 2014 Feb 24;9(2):e89880. doi: 10.1371/journal.pone.0089880. eCollection 2014.

26.

Src signaling pathways in prostate cancer.

Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG.

Cancer Metastasis Rev. 2014 Sep;33(2-3):595-606. doi: 10.1007/s10555-013-9481-1. Review.

27.

Targeting SRC and tubulin in mucinous ovarian carcinoma.

Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK.

Clin Cancer Res. 2013 Dec 1;19(23):6532-43. doi: 10.1158/1078-0432.CCR-13-1305. Epub 2013 Oct 7.

28.

Inhibition of cell adhesion by a cadherin-11 antibody thwarts bone metastasis.

Lee YC, Bilen MA, Yu G, Lin SC, Huang CF, Ortiz A, Cho H, Song JH, Satcher RL, Kuang J, Gallick GE, Yu-Lee LY, Huang W, Lin SH.

Mol Cancer Res. 2013 Nov;11(11):1401-11. doi: 10.1158/1541-7786.MCR-13-0108. Epub 2013 Aug 2.

29.

Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH.

Cancer Discov. 2013 Aug;3(8):849-61. doi: 10.1158/2159-8290.CD-12-0460. Epub 2013 Jun 28. Review.

30.

Src inhibitors in suppression of papillary thyroid carcinoma growth.

Henderson YC, Toro-Serra R, Chen Y, Ryu J, Frederick MJ, Zhou G, Gallick GE, Lai SY, Clayman GL.

Head Neck. 2014 Mar;36(3):375-84. doi: 10.1002/hed.23316. Epub 2013 Jun 1.

31.

RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B.

Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, Bornmann WG, Yu-Lee LY, Gallick GE, Zhang W, Lin SH, Kuang J.

Oncogene. 2014 May 1;33(18):2385-94. doi: 10.1038/onc.2013.182. Epub 2013 May 27.

32.

Ligand-independent activation of MET through IGF-1/IGF-1R signaling.

Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE.

Int J Cancer. 2013 Oct 1;133(7):1536-46. doi: 10.1002/ijc.28169. Epub 2013 Apr 17.

33.

Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer.

Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE.

Prostate. 2013 Jun;73(9):979-85. doi: 10.1002/pros.22645. Epub 2013 Jan 31.

34.

Src activation by β-adrenoreceptors is a key switch for tumour metastasis.

Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK.

Nat Commun. 2013;4:1403. doi: 10.1038/ncomms2413. Erratum in: Nat Commun. 2013;4:1932. Shazhad, Mian M K [corrected to Shahzad, Mian M K].

35.

Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis.

Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, McIntyre BW, Logothetis CJ, Gallick GE, Lin SH.

Mol Cancer Res. 2013 Apr;11(4):405-17. doi: 10.1158/1541-7786.MCR-12-0551. Epub 2013 Jan 21.

36.

Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.

Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE.

PLoS One. 2012;7(12):e51189. doi: 10.1371/journal.pone.0051189. Epub 2012 Dec 26.

37.

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S.

Clin Cancer Res. 2013 Feb 1;19(3):657-67. doi: 10.1158/1078-0432.CCR-11-1446. Epub 2012 Dec 18.

38.

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R.

Invest New Drugs. 2013 Aug;31(4):918-26. doi: 10.1007/s10637-012-9898-3. Epub 2012 Nov 20.

39.

A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.

Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS, Wei W, Johnson MM, Wittemer SM, Vardeleon A, Reckeweg A, Colevas AD.

Melanoma Res. 2012 Aug;22(4):294-301. doi: 10.1097/CMR.0b013e32835312e4.

40.

Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Gallick GE, Corn PG, Zurita AJ, Lin SH.

Future Med Chem. 2012 Jan;4(1):107-19. doi: 10.4155/fmc.11.161.

41.

The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials.

Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE.

Expert Opin Investig Drugs. 2011 Dec;20(12):1677-84. doi: 10.1517/13543784.2011.631523. Epub 2011 Oct 28. Review.

42.

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.

Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ.

Cancer. 2012 Jan 1;118(1):63-71. doi: 10.1002/cncr.26204. Epub 2011 Jul 25.

43.

Novel therapies for metastatic castrate-resistant prostate cancer.

Dayyani F, Gallick GE, Logothetis CJ, Corn PG.

J Natl Cancer Inst. 2011 Nov 16;103(22):1665-75. doi: 10.1093/jnci/djr362. Epub 2011 Sep 13. Review.

44.

Targeting SRC in mucinous ovarian carcinoma.

Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK.

Clin Cancer Res. 2011 Aug 15;17(16):5367-78. doi: 10.1158/1078-0432.CCR-10-3176. Epub 2011 Jul 7.

45.

Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy.

Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, Gallick GE, Wang H, McConkey DJ, Hwang R, Logsdon C, Abbruzzesse J, Fleming JB.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S395-403. doi: 10.1245/s10434-011-1839-4. Epub 2011 Jun 24.

46.

ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.

Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE.

PLoS One. 2011;6(6):e20636. doi: 10.1371/journal.pone.0020636. Epub 2011 Jun 13.

47.

BMP4 promotes prostate tumor growth in bone through osteogenesis.

Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, Gallick GE, Maity SN, Lin SH.

Cancer Res. 2011 Aug 1;71(15):5194-203. doi: 10.1158/0008-5472.CAN-10-4374. Epub 2011 Jun 13.

48.

Pre-clinical mouse models of human prostate cancer and their utility in drug discovery.

Park SI, Kim SJ, McCauley LK, Gallick GE.

Curr Protoc Pharmacol. 2010 Dec;Chapter 14:Unit 14.15. doi: 10.1002/0471141755.ph1415s51.

49.

Steps in prostate cancer progression that lead to bone metastasis.

Jin JK, Dayyani F, Gallick GE.

Int J Cancer. 2011 Jun 1;128(11):2545-61. doi: 10.1002/ijc.26024. Epub 2011 Mar 28. Review.

50.

Functional roles of Src and Fgr in ovarian carcinoma.

Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2011 Apr 1;17(7):1713-21. doi: 10.1158/1078-0432.CCR-10-2081. Epub 2011 Feb 7.

Supplemental Content

Loading ...
Support Center